Abstract: A social media platform for immersive media stores immersive videos (e.g., 360 video) and embedded affordances for the immersive videos. The platform includes a publisher user interface that enables publisher users to upload immersive videos to the database and embed affordances into the immersive videos at locations that are defined both spatially and temporally. Each affordance is discoverable by viewer users, has an interactive user interface, and has one or more corresponding rewards. The platform includes a viewer user interface that enables viewer users to select and play immersive videos and navigate to different portions of a playing immersive video using a visibility window, which displays a respective selected portion of the playing immersive video based on placement of the visibility window. In response to a first user action to activate a first affordance of the playing immersive video, the platform initiates a reward corresponding to the first affordance.

Abstract: A computing system has memory, a microphone, and an image sensor. A process displays an immersive media customization user interface, and plays a 360 video. In response to a first user action, the process captures a freeze frame of the 360 video at a specific moment. In response to a second user action, the process starts recording a customized video of the captured freeze frame in real time according to a dynamically adjustable visibility window of the captured freeze frame. While recording the customized video, a user adjusts the visibility window. After recording, a user annotates the customized video, including one or more of: adding a visual overlay in a portion of the customized video, where the visual overlay is a recorded video of the user; adding an audio overlay (e.g., user comments); and adding text or an image. The process transmits the customized video to another computing system.

Abstract: This present invention relates to pharmaceutical compositions comprising cyclophosphamide alone and/or in combination with one or more pharmaceutical active ingredients and one or more pharmaceutically acceptable excipients wherein the cyclophosphamide has D90 particle size less than 100 microns.

Abstract: A computing system has memory, a microphone, and an image sensor. A process displays an immersive media customization user interface, and plays a 360 video. In response to a first user action, the process captures a freeze frame of the 360 video at a specific moment. In response to a second user action, the process starts recording a customized video of the captured freeze frame in real time according to a dynamically adjustable visibility window of the captured freeze frame. While recording the customized video, a user adjusts the visibility window. After recording, a user annotates the customized video, including one or more of: adding a visual overlay in a portion of the customized video, where the visual overlay is a recorded video of the user; adding an audio overlay (e.g., user comments); and adding text or an image. The process transmits the customized video to another computing system.

Abstract: A computing device has memory, a microphone, and an image sensor. A process plays an immersive video in a user interface region, which displays a portion of the immersive video according to a user selected visibility window. While playing the immersive video, the user adjusts the window, and the process records information that identifies placement of the window within the immersive video. The process records audio provided by the user and records video of the user. The process uses the information that identifies placement of the window to form a customized video including what was displayed in the window while playing the immersive video. The customized video also includes a visual overlay in a peripheral portion of the customized video, which includes the recorded video of the user. The customized video also includes an audio overlay using the recorded audio. The process transmits the customized video to another computer.

Abstract: A social media platform for immersive media stores immersive videos (e.g., 360 video) and embedded affordances for the immersive videos. The platform includes a publisher user interface that enables publisher users to upload immersive videos to the database and embed affordances into the immersive videos at locations that are defined both spatially and temporally. Each affordance is discoverable by viewer users, has an interactive user interface, and has one or more corresponding rewards. The platform includes a viewer user interface that enables viewer users to select and play immersive videos and navigate to different portions of a playing immersive video using a visibility window, which displays a respective selected portion of the playing immersive video based on placement of the visibility window. In response to a first user action to activate a first affordance of the playing immersive video, the platform initiates a reward corresponding to the first affordance.

Abstract: This present invention relates to pharmaceutical compositions comprising cyclophosphamide alone and/or in combination with one or more pharmaceutical active ingredients and one or more pharmaceutically acceptable excipients wherein the cyclophosphamide has D90 particle size less than 100 microns.

Abstract: A pharmaceutical compositions having fixed dose combinations of capecitabine and cyclophosphamide, processes for the preparation thereof, and their use to treat cancer diseases.

Abstract: The present invention relates to a method for preparing asymmetric multi-layered osmotic tablets using rapid and accurate determination of the orientation of tablets with respect to different internal formulation layers proximate to the opposite curved surfaces. In particular, the invention relates to detect degree of curvature using an image recognition system and drill the desired surface using a laser beam.

Abstract: The present invention relates to an improved process for preparing a polypeptide or pharmaceutically acceptable salt thereof comprising L-tyrosine, L-alanine, L-glutamate, and L-lysine. The polypeptide or pharmaceutically acceptable salt thereof is preferably glatiramer acetate.

Abstract: The invention provides an Olanzapine pseudopolymoph Form E. The invention provides methods of preparing polymorphic Olanzapine Form E employing rapid crystallization and seeding. The invention provides methods of preparing anhydrous Olanzapine Form I from the Olanzapine Form E by step-wise drying.

Abstract: The present invention relates to processes for preparing a polypeptide or pharmaceutically acceptable salt thereof comprising L-tyrosine, L-alanine, L-glutamate and L-lysine. The polypeptide or pharmaceutically acceptable salt thereof is preferably glatiramer acetate.

Abstract: A pharmaceutical composition having improved solubility comprising a hydrophobic drug or pharmaceutically acceptable salt thereof and a compound having at least one carboxylic acid moiety, wherein the molar ratio of the compound having at least one carboxylic acid moiety to the hydrophobic drug or pharmaceutically acceptable salt thereof is from about 0.1:1 to about 25:1. The pharmaceutical composition exhibits rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.

Abstract: An extended-release antibiotic composition comprising at least one antibiotic, and greater than 50 weight percent, based on the total weight of the composition, of a polymer component, wherein said polymer component comprises at least one pharmaceutically acceptable hydrophilic polymer, and said polymer component has a viscosity of less than about 50 cps.

Abstract: This disclosure relates to stable pharmaceutical formulations of the drug fosinopril sodium comprising a lubricant which is sodium stearate or a mixture composed of stearic acid esters, propylene glycol monoesters, distilled monoglycerides, sodium stearoyl lactylate, and silicon dioxide.

Abstract: Processes for the preparation of Venlafaxine (IX) via the novel epoxy-nitrile intermediate (I), which when subjected to hydrogenation forms compound (X), and may subsequently be reduced to yield the desired product (IX). The epoxy-nitrile intermediate (I) itself may be synthesized via various alternative reaction strategies, from a range of starting materials. E.g. 4-methoxy-benzaldehyde (VI), upon treatment with cyclohexyl magnesium bromide yields compound (V). This in turn may be oxidized to yield compound (III), which forms compound (II) on treatment with an (x-keto-halogenation agent. Cyanation of compound (II), then yields the desired epoxy nitrile intermediate (I), from which Venlafaxine (IX) may be synthesized.

Abstract: Processes for the preparation of Venlafaxine (IX) via the novel epoxy-nitrile intermediate (I), which when subjected to hydrogenation forms compound (X), and may subsequently be reduced to yield the desired product (IX). The epoxy-nitrile intermediate (I) itself may be synthesised via various alternative reaction strategies, from a range of starting materials. E.g. 4-methoxy-benzaldehyde (VI), upon treatment with cyclohexyl magnesium bromide yields compound (V). This in turn may be oxidised to yield compound (III), which forms compound (II) on treatment with an (x-keto-halogenation agent. Cyanation of compound (II), then yields the desired epoxy nitrile intermediate (I), from which Venlafaxine (IX) may be synthesised.

Abstract: A novel pharmaceutical composition including thieno-pyridine derivatives, primarily ticlopidine hydrochloride, having no other organic or inorganic acid stabilizing agents or metal stearates. The stable pharmaceutical composition also includes hydrogenated vegetable oil as lubricant and other suitable non-ionic inert pharmaceutical excipients.

Abstract: In transmitting information over a cellular communications channel to an opposite endpoint, a modem's autorating routine is "data-driven." In particular, when the amount of information to transmit to the opposite endpoint is low, the modem's data rate is low e.g., 4800 bps, and the modem's ability to autorate upwards, i.e., fallforward, is disabled. However, when the amount of information to transmit to the opposite endpoint is high the modem's ability to fallforward is enabled so that the modem's data rate can increase to the highest permissible data rate for the cellular channel in order to transmit large blocks of information.